Results of analysis of effectiveness and safety of direct oral anticoagulants (DOAC) versus phenprocoumon
| Treatment | Propensity score matching | Cox regression | ||||
| RRR | ARR (95% CI) | NNT | P value | HR(95 % CI) | P value | |
| Thromboembolic events | ||||||
| DOAC | −5.0% | −0.1% (−0.4% to 0.2%) | −934 | 0.513 | ||
| Apixaban | −7.4% | −0.2% (−0.5% to 0.2%) | −650 | 0.381 | ||
| Dabigatran | −21.2% | −0.5% (−1.6% to 0.5%) | −189 | 0.344 | ||
| Edoxaban | −7.4% | −0.1% (−0.6% to 0.3%) | −738 | 0.588 | ||
| Rivaroxaban | −6.3% | −0.1% (−0.5% to 0.2%) | −809 | 0.508 | ||
| Death | ||||||
| DOAC | 2.9% | 0.2% (−0.3% to 0.6%) | 612 | 0.516 | ||
| Apixaban | 9.1% | 0.5% (0.0% to 1.0%) | 210 | 0.062 | ||
| Dabigatran | 26.8% | 0.7% (−0.2% to 1.7%) | 139 | 0.150 | ||
| Edoxaban | 18.5% | 0.7% (0.1% to 1.3%) | 142 | 0.022 | ||
| Rivaroxaban | −8.3% | −0.4% (−0.9% to 0.2%) | −275 | 0.169 | 1.21(1.10 to 1.34) | <0.001* |
| Bleeding | ||||||
| DOAC | 32.5% | 1.0% (0.7% to 1.3%) | 101 | <0.001* | 0.67(0.59 to 0.76) | <0.001* |
| Apixaban | 44.4% | 1.3% (0.9% to 1.6%) | 78 | <0.001* | 0.54(0.46 to 0.63) | <0.001* |
| Dabigatran | 38.9% | 0.7% (−0.1% to 1.4%) | 149 | 0.086 | ||
| Edoxaban | 24.7% | 0.5% (0.1% to 1.0%) | 185 | 0.019 | ||
| Rivaroxaban | 24,3% | 0.6% (0.3% to 1.0%) | 156 | <0.001* | 0.83(0.72 to 0.97) | 0.015 |
*Adjusted p=0.003. Note: Results of comparison after propensity score matching and the significant results of the Cox regression models. Bold text highlights statistically significant results. Adjustment of p value with Bonferroni correction.
ARR, absolute risk reduction; DOAC, direct oral anticoagulant; NNT, number needed to treat; RRR, relative risk reduction.